Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Chronic gingivostomatitis is a common infection of mouth and gums, leading to drooling and swelling. Sometimes lesions in the mouth resembles the canker sores. This infection is common among children. Increasing incidence of gingivostomatitis is expected to boost the market growth. For instance, according to the Journal of Dental Health, Oral Disorders & Therapy, an article - A Case Report on Symptomatic Primary Herpetic Gingivostomatitis, published in December 2017, states that primary herpetic gingivostomatitis (PHG) is a common pediatric infection usually seen before 6 years of age, which is mostly i.e. 90% caused by Herpes Simplex Virus (HSV) type 1.

The global chronic gingivostomatitis treatment market is estimated to be valued at US$ 12,922.5 million in 2020 and is expected to exhibit a CAGR of 6.5% during the forecast period (2020-2027).

Figure 1. Global Chronic Gingivostomatitis Treatment Market Share (%), by Region, 2020

Chronic Gingivostomatitis Treatment  | Coherent Market Insights

Major players offering effective products is expected to propel growth of the global chronic gingivostomatitis treatment market

Major players in the market are focused on offering effective products for chronic gingivostomatitis treatment, which is expected to boost the market growth over the forecast period. For instance, GlaxoSmithKline offers Zovirax, a cream with active ingredient, aciclovir, for antiviral treatment for cold sores.

Moreover, other major players also offers generic drugs from other manufacturers. For instance, HERITAGE PHARMS INC offers ZOVIRAX (acyclovir), a suspension, a generic version of the GlaxoSmithKlines’ Zovirax.

request-sample

Chronic Gingivostomatitis Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 12,922.5 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.5% 2027 Value Projection: US$ 20,175.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Physical Examination, Microbial Culture, Biopsy, Others.
  • By Treatment: Non-steroidal Anti-inflammatory Drugs, Antiviral, Antibacterial, Others.
  • By End User: Hospitals & Clinics, Academic & Research, Others.
Companies covered:

Pfizer Inc., Taj Pharmaceutical limited, Ciron pharma, Johnson & Johnson, GlaxoSmithKline PLC, Merck & CO., Inc., Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, and AstraZeneca Plc.

Growth Drivers:
  • Rising incidence of chronic gingivostomatitis
Restraints & Challenges:
  • Misidentification or diagnosis of chronic gingivostomatitis

Figure 2. Global Chronic Gingivostomatitis Treatment Market Share (%), by Treatment, 2020

Chronic Gingivostomatitis Treatment  | Coherent Market Insights

Increasing incidence of chronic gingivostomatitis in North America is expected to boost the market growth

North America is expected to hold dominant position in the global chronic gingivostomatitis treatment market, owing to increasing new cases of chronic gingivostomatitis in the region. For instance, according to the Western Journal of Emergency Medicine, an article - Cost of Routine Herpes Simplex Virus Infection Visits to U.S. ED 2006-2013, published in 2018, reports that there were 115,726 number of patient visits with primary diagnosis during 2006-2013 in the U.S.

Global Chronic Gingivostomatitis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has caused an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global chronic gingivostomatitis treatment market during the forecast period.

Key Players

Major players operating in the global chronic gingivostomatitis treatment market include Pfizer Inc., Taj Pharmaceutical limited, Ciron pharma, Johnson & Johnson, GlaxoSmithKline PLC, Merck & CO., Inc., Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, and AstraZeneca Plc.

Gingivostomatitis is a contagious mouth infection, which causes painful sores, blisters, and swelling in the tongue and uvula. It usually spreads through the saliva of an infected individual or by direct contact with a lesion or sore. Gingivostomatitis is also called as herpetic, which is caused by herpes simplex virus and is the most common cause of gingivostomatitis. Gingivostomatitis is the most common among young children, usually under 6 years old, but it may also occur in adults. Geriatric people may experience severe symptoms than adults and children.

Market Dynamics

Rising incidence of gingivostomatitis caused by herpes simplex virus (HSV) is expected to drive the chronic gingivostomatitis treatment market growth. For instance, according to the International Journal of Dentistry, an article published in October 2016, reports that over 90% of gingivostomatitis cases are caused by herpes simplex virus (HSV) type 1 and the remainder are caused by herpes simplex virus (HSV) type 2.

However, lack of identification or diagnosis of chronic gingivostomatitis are expected to hinder the market growth. For instance, according to the Journal of Dental Health Oral Disorders & Therapy, an article published in 2017, states that chronic gingivostomatitis may be asymptomatic in some instances, may be unnoticed in some instances, and sometimes get misdiagnosed with other chronic mouth ulcers.

Key features of the study:

  • This report provides in-depth analysis of the global chronic gingivostomatitis treatment  market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global chronic gingivostomatitis treatment  market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Pfizer Inc., Taj Pharmaceutical limited, Ciron pharma, Johnson & Johnson, GlaxoSmithKline PLC, Merck & CO., Inc., Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, and AstraZeneca Plc. among others
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global chronic gingivostomatitis treatment  market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic gingivostomatitis treatment market

Detailed Segmentation:

  • Global Chronic Gingivostomatitis Treatment Market, By Diagnosis:
    • Physical Examination
    • Microbial Culture
    • Biopsy
    • Others
  • Global Chronic Gingivostomatitis Treatment Market, By Treatment:
    • Non-steroidal Anti-inflammatory Drugs
    • Antiviral
    • Antibacterial
    • Others
  • Global Chronic Gingivostomatitis Treatment Market, By End User:
    • Hospitals & Clinics
    • Academic & Research
    • Others
  • Global Chronic Gingivostomatitis Treatment Market, By Region:
    • North America
      • By Diagnosis:
        • Physical Examination
        • Microbial Culture
        • Biopsy
        • Others
      • By Treatment:
        • Non-steroidal Anti-inflammatory Drugs
        • Antiviral
        • Antibacterial
        • Others
      • By End User:
        • Hospitals & Clinics
        • Academic & Research
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Diagnosis:
        • Physical Examination
        • Microbial Culture
        • Biopsy
        • Others
      • By Treatment:
        • Non-steroidal Anti-inflammatory Drugs
        • Antiviral
        • Antibacterial
        • Others
      • By End User:
        • Hospitals & Clinics
        • Academic & Research
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
      • By Diagnosis:
        • Physical Examination
        • Microbial Culture
        • Biopsy
        • Others
      • By Treatment:
        • Non-steroidal Anti-inflammatory Drugs
        • Antiviral
        • Antibacterial
        • Others
      • By End User:
        • Hospitals & Clinics
        • Academic & Research
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Diagnosis:
        • Physical Examination
        • Microbial Culture
        • Biopsy
        • Others
      • By Treatment:
        • Non-steroidal Anti-inflammatory Drugs
        • Antiviral
        • Antibacterial
        • Others
      • By End User:
        • Hospitals & Clinics
        • Academic & Research
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Diagnosis:
        • Physical Examination
        • Microbial Culture
        • Biopsy
        • Others
      • By Treatment:
        • Non-steroidal Anti-inflammatory Drugs
        • Antiviral
        • Antibacterial
        • Others
      • By End User:
        • Hospitals & Clinics
        • Academic & Research
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Diagnosis:
        • Physical Examination
        • Microbial Culture
        • Biopsy
        • Others
      • By Treatment:
        • Non-steroidal Anti-inflammatory Drugs
        • Antiviral
        • Antibacterial
        • Others
      • By End User:
        • Hospitals & Clinics
        • Academic & Research
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Taj Pharmaceutical limited.
    • Ciron pharma
    • Johnson & Johnson
    • GlaxoSmithKline PLC
    • Merck & CO., Inc.
    • Novartis AG
    • Hoffman La Roche AG
    • Eli Lily and Company
    • AstraZeneca Plc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Diagnosis
      • Market Snippet, By Treatment
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
    • Regulatory Scenario
    • New Product Launches
    • Collaborations and Agreements
    • Market Trends
  4. Global Chronic Gingivostomatitis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Market Scenario
    • Impact of COVID-19 Market on the Chronic Gingivostomatitis Treatment Products
  5. Global Chronic Gingivostomatitis Treatment Market, By Diagnosis, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Physical Examination
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Microbial Culture
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Biopsy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Chronic Gingivostomatitis Treatment Market, By Treatment, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Non-steroidal Anti-inflammatory Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Antiviral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Antibacterial
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Chronic Gingivostomatitis Treatment Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals & Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Academic & Research
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Chronic Gingivostomatitis Treatment Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Taj Pharmaceutical limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ciron pharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline PLC
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & CO., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffman La Roche AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lily and Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AstraZeneca Plc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 30 figures on "Chronic Gingivostomatitis Treatment Market” - Global forecast to 2027

FAQgrowicon

Frequently Asked Questions

The global chronic gingivostomatitis treatment market is expected to exhibit a CAGR of 6.5% during the forecast period (2020-2027).
The global chronic gingivostomatitis treatment market is estimated to be valued at US$ 12,922.5 million in 2020.
Rising incidence of chronic gingivostomatitis is favoring the market growth.
Non-steroidal anti-inflammatory drugs segment is expected to be the leading segment in the global chronic gingivostomatitis treatment market during the forecast period (2020-2027).
North America chronic gingivostomatitis treatment market holds the largest market share in the global chronic gingivostomatitis treatment market.
hich are the major players operating in the global chronic gingivostomatitis treatment market?
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.